Literature DB >> 21047033

Human papillomavirus disease and vaccines in adolescents.

Anna-Barbara Moscicki1.   

Abstract

Review of the most recent evidence indicates that screening for cervical cancer in females younger than 21 years of age likely leads to more harm than good. In addition, screening during adolescence has not lead to decreased cervical cancers in this age group. The rate of cervical cancer remains extremely low in adolescents. In contrast, abnormal cytology is extremely common, of which most is benign. Hence, referral to colposcopy is unnecessary and costly. New guidelines recommend cervical cancer screening to start at the age of 21 years and to not be based on sexual behavior. The exception is for immunocompromised girls, who should be screened once intercourse is initiated, since they are at increased risk for cervical cancer. Recently, we have also broadened our understanding about human papillomavirus-associated disease in men. In this chapter, we cover the advances in science that have led to new screening recommendation for cervical cancer and the advances in prevention: vaccines for both adolescent women and men.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21047033      PMCID: PMC3057670     

Source DB:  PubMed          Journal:  Adolesc Med State Art Rev        ISSN: 1934-4287


  94 in total

1.  Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study.

Authors:  Alexandra de Pokomandy; Danielle Rouleau; George Ghattas; Sylvie Vézina; Pierre Coté; John Macleod; Guy Allaire; Eduardo L Franco; François Coutlée
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

Review 2.  Interaction of human papillomaviruses with the host immune system: a well evolved relationship.

Authors:  Ian H Frazer
Journal:  Virology       Date:  2008-11-04       Impact factor: 3.616

3.  Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods.

Authors:  Meg Watson; Mona Saraiya; Faruque Ahmed; Cheryll J Cardinez; Marsha E Reichman; Hannah K Weir; Thomas B Richards
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

Review 4.  The epidemiology of anal human papillomavirus and related neoplasia.

Authors:  Joel M Palefsky; Mary Rubin
Journal:  Obstet Gynecol Clin North Am       Date:  2009-03       Impact factor: 2.844

5.  Risks for cervical intraepithelial neoplasia 3 among adolescents and young women with abnormal cytology.

Authors:  Anna-Barbara Moscicki; Yifei Ma; Charles Wibbelsman; Adaleen Powers; Teresa M Darragh; Sepideh Farhat; Ruth Shaber; Stephen Shiboski
Journal:  Obstet Gynecol       Date:  2008-12       Impact factor: 7.661

6.  Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection.

Authors:  Sepideh Farhat; Mayumi Nakagawa; Anna-Barbara Moscicki
Journal:  Int J Gynecol Cancer       Date:  2009-05       Impact factor: 3.437

7.  Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies.

Authors: 
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-31       Impact factor: 4.254

8.  Factors that influence the rate of epithelial maturation in the cervix in healthy young women.

Authors:  Loris Y Hwang; Yifei Ma; Susanna Miller Benningfield; Lisa Clayton; Evelyn N Hanson; Julie Jay; Janet Jonte; Cheryl Godwin de Medina; Anna-Barbara Moscicki
Journal:  J Adolesc Health       Date:  2009-02       Impact factor: 5.012

9.  Duration and clearance of anal human papillomavirus (HPV) infection among women: the Hawaii HPV cohort study.

Authors:  Yurii B Shvetsov; Brenda Y Hernandez; Katharine McDuffie; Lynne R Wilkens; Xuemei Zhu; Lily Ning; Jeffrey Killeen; Lori Kamemoto; Marc T Goodman
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

10.  Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2.

Authors:  Philip E Castle; Mark Schiffman; Cosette M Wheeler; Diane Solomon
Journal:  Obstet Gynecol       Date:  2009-01       Impact factor: 7.623

View more
  4 in total

1.  Quality of life valuations of HPV-associated cancer health states by the general population.

Authors:  E Lynne Conway; K Chip Farmer; William J Lynch; Guy L Rees; Gerard Wain; Jane Adams
Journal:  Sex Transm Infect       Date:  2012-05-29       Impact factor: 3.519

2.  Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.

Authors:  Kihyuck Kwak; Rosie Jiang; Subhashini Jagu; Joshua W Wang; Chenguang Wang; Neil D Christensen; Richard B S Roden
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

3.  Comprehensive clinic-pathological characteristics of cervical cancer in southwestern China and the clinical significance of histological type and lymph node metastases in young patients.

Authors:  LingYun Yang; XiBiao Jia; NingWei Li; Cen Chen; Yi Liu; HongJing Wang
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

4.  Human papillomavirus vaccine uptake in adolescence and adherence to cervical cancer screening in Switzerland: a national cross-sectional survey.

Authors:  Monica N Wymann; Anne Spaar Zographos; Ekkehardt Altpeter; Virginie Masserey Spicher; Nicola Low; Mirjam Mäusezahl-Feuz
Journal:  Int J Public Health       Date:  2017-11-06       Impact factor: 3.380

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.